統合腫瘍学における菌類由来サプリメント
Caroline Mohammed1, Ashley E Aaroe2, Greg Buchold2
1Department of Neurology, University of North Carolina at Chapel Hill, NC.
The American journal of medicine
|January 14, 2026
まとめ
菌類サプリメントは、免疫調節作用、神経保護作用、抗酸化作用を提供し、がん患者に有望である。これらの自然療法を従来の癌治療に統合し、患者の幸福感を向上させるためには、さらなる研究が必要である。
科学分野:
- 統合腫瘍学
- 薬理学
- 菌類学
背景:
- がん患者のサポートのための菌類由来サプリメントへの関心の高まり。
- 前臨床および臨床研究は、菌類の免疫調節作用、神経保護作用、抗酸化作用を示唆している。
- これらの自然なアプローチの現在の癌治療への統合は限定的である。
研究 の 目的:
- がん患者のケアにおける菌類サプリメントの潜在的な利点を強調すること。
- 補完療法としての菌類の利用に関するさらなる調査を奨励すること。
- 統合医療の枠組み内に菌類由来サプリメントを統合することを促進すること。
主な方法:
- 菌類の活性に関する前臨床動物研究のレビュー。
- 菌類の利点を支持するヒト臨床研究の分析。
- 肯定的な患者の幸福感への影響を示す例の収集。
主要な成果:
- 菌類サプリメントは、顕著な免疫調節作用、神経保護作用、抗酸化作用を示す。
- 動物およびヒトを対象とした研究の両方からのエビデンスが、これらの治療的可能性を支持している。
- 文書化された症例は、患者の全体的な幸福感への肯定的な貢献を示している。
結論:
- 菌類由来サプリメントは、がん患者のケアを強化するための有望な道を提供する。
- これらの天然物のさらなるヘルスケア専門家による利用と調査が必要である。
- 菌類サプリメントを癌治療計画に統合することは、患者の幸福感をサポートできる。
関連する概念動画
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Fungal Phylum Microsporidia
425
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
425


